openPR Logo
Press release

Sporadic Inclusion Body Myositis Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working, DelveInsight | Novartis Pharmaceutical, Regeneron Pharmaceuticals, ZevraDenmark, Abcuro Inc., Syneos Health, Argenx, Amgen, Immunoforge Co. Lt

04-22-2025 04:00 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Sporadic Inclusion Body Myositis Market, DelveInsight

Sporadic Inclusion Body Myositis Market, DelveInsight

Sporadic Inclusion Body Myositis emerging therapies are expected to boost the Sporadic Inclusion Body Myositis Market in the upcoming years.

DelveInsight has launched a new report on "Sporadic Inclusion Body Myositis - Market Insights, Epidemiology, and Market Forecast-2032" that delivers an in-depth understanding of the Sporadic Inclusion Body Myositis, historical and forecasted epidemiology as well as the Sporadic Inclusion Body Myositis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Request for a sporadic inclusion body myositis market sample page @ https://www.delveinsight.com/report-store/sporadic-inclusion-body-myositis-sibm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Sporadic Inclusion Body Myositis Market Report:

In May 2023, ZevraDenmark announced a Phase 2 clinical trial to evaluate the safety and efficacy of the investigational drug Arimoclomol in patients with Inclusion Body Myositis (IBM).
In June 2023, Abcuro Inc. launched a Phase 2 & 3 clinical trial for ABC008. This randomized, double-blind, placebo-controlled, multicenter study aims to assess the effectiveness and safety of ABC008 in treating patients with Inclusion Body Myositis (IBM).
In July 2023, Argenx began a Phase 2 & 3 clinical trial for EFG PH20 SC and PBO. The study's goal is to evaluate the treatment response of efgartigimod PH20 SC compared to a placebo in individuals with Idiopathic Inflammatory Myopathy (IIM), including various IIM subtypes like dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), and certain forms of polymyositis (PM), such as antisynthetase syndrome (ASyS). The treatment response will be measured using the Total Improvement Score (TIS).
Key Sporadic Inclusion Body Myositis companies such as Novartis Pharmaceutical, Regeneron Pharmaceuticals, ZevraDenmark, Abcuro Inc., Syneos Health, Argenx, Amgen, Immunoforge Co. Ltd, Janssen Research & Development LLC, Pfizer, Bristol-Myers Squibb, Eli Lilly and Company, Roche Pharma AG, Octapharma, Biogen, Kezar Life Sciences Inc., and others are evaluating new drugs for Sporadic Inclusion Body Myositis to improve the treatment landscape.
Key benefits of the Sporadic Inclusion Body Myositis market report:
Sporadic Inclusion Body Myositis market report covers a descriptive overview and comprehensive insight of the Sporadic Inclusion Body Myositis Epidemiology and Sporadic Inclusion Body Myositis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Sporadic Inclusion Body Myositis market report provides insights on the current and emerging therapies.
Sporadic Inclusion Body Myositis market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Sporadic Inclusion Body Myositis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Sporadic Inclusion Body Myositis market.

Got queries? Click here to know more about the Sporadic Inclusion Body Myositis Market Landscape @ https://www.delveinsight.com/sample-request/sporadic-inclusion-body-myositis-sibm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Sporadic Inclusion Body Myositis Overview

The treatment market for Sporadic Inclusion Body Myositis has seen notable progress in recent years, providing new hope for patients facing this rare and debilitating condition. Sporadic Inclusion Body Myositis is a chronic, progressive inflammatory muscle disorder that predominantly affects older adults, leading to muscle weakness and deterioration. Increased understanding of the disease's underlying mechanisms has paved the way for the development of targeted therapies and innovative treatment strategies.

Sporadic Inclusion Body Myositis Market Outlook

The outlook for the Sporadic Inclusion Body Myositis (sIBM) market is experiencing notable advancements and challenges within the neuromuscular disorder sector. sIBM is a rare, progressive muscle-wasting disease that predominantly affects older adults. Although it remains difficult to diagnose and treat, ongoing medical research has led to a deeper understanding of the disease's underlying mechanisms.

This section provides an in-depth analysis of the sIBM market trends for each approved drug and late-stage pipeline therapy. It evaluates their impact based on factors such as annual therapy costs, inclusion and exclusion criteria, mechanisms of action, patient compliance rates, growing market demand, increasing patient population, targeted patient segments, anticipated launch dates, competition with other therapies, brand value, and the perspectives of key opinion leaders. The sIBM market data is presented with relevant tables and graphs for a clear and comprehensive overview of the market.
Discover how the sporadic inclusion body myositis market is rising in the upcoming years @ https://www.delveinsight.com/report-store/sporadic-inclusion-body-myositis-sibm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Sporadic Inclusion Body Myositis Market Report

Study Period: 2019-2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Sporadic Inclusion Body Myositis Companies: Novartis Pharmaceutical, Regeneron Pharmaceuticals, ZevraDenmark, Abcuro Inc., Syneos Health, Argenx, Amgen, Immunoforge Co. Ltd, Janssen Research & Development LLC, Pfizer, Bristol-Myers Squibb, Eli Lilly and Company, Roche Pharma AG, Octapharma, Biogen, Kezar Life Sciences Inc., and others
Sporadic Inclusion Body Myositis Therapeutic Assessment: Sporadic Inclusion Body Myositis current marketed and Sporadic Inclusion Body Myositis emerging therapies
Sporadic Inclusion Body Myositis Market Dynamics: Sporadic Inclusion Body Myositis market drivers and Sporadic Inclusion Body Myositis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Sporadic Inclusion Body Myositis Unmet Needs, KOL's views, Analyst's views, Sporadic Inclusion Body Myositis Market Access and Reimbursement

Download our report @ https://www.delveinsight.com/sample-request/sporadic-inclusion-body-myositis-sibm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Sporadic Inclusion Body Myositis Patient Share (%) Overview at a Glance
5. Sporadic Inclusion Body Myositis Market Overview at a Glance
6. Sporadic Inclusion Body Myositis Disease Background and Overview
7. Sporadic Inclusion Body Myositis Epidemiology and Patient Population
8. Country-Specific Patient Population of Sporadic Inclusion Body Myositis
9. Sporadic Inclusion Body Myositis Current Treatment and Medical Practices
10. Unmet Needs
11. Sporadic Inclusion Body Myositis Emerging Therapies
12. Sporadic Inclusion Body Myositis Market Outlook
13. Country-Wise Sporadic Inclusion Body Myositis Market Analysis (2019-2032)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Sporadic Inclusion Body Myositis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Sporadic Inclusion Body Myositis Market Outlook 2032 https://www.delveinsight.com/report-store/sporadic-inclusion-body-myositis-sibm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Sporadic Inclusion Body Myositis Pipeline Insights, DelveInsight

"Sporadic Inclusion Body Myositis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Sporadic Inclusion Body Myositis market. A detailed picture of the Sporadic Inclusion Body Myositis pipeline landscape is provided, which includes the disease overview and Sporadic Inclusion Body Myositis treatment guidelines.

Contact Info:

Kritika Rehani, Team Leader Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Sporadic Inclusion Body Myositis Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working, DelveInsight | Novartis Pharmaceutical, Regeneron Pharmaceuticals, ZevraDenmark, Abcuro Inc., Syneos Health, Argenx, Amgen, Immunoforge Co. Lt here

News-ID: 3981899 • Views:

More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market

All 5 Releases


More Releases for Inclusion

Schneider Electric Bags Gender Inclusion Award
Schneider Electric, a global leader in energy management and automation, has been recognised for its commitment to gender diversity and inclusion across its African operations. The company was named the recipient of the Gender Leader Award at the 2025 edition of the Africa CEO Forum, held in Abidjan, Cote d'Ivoire, from May 12 to 13. The award, which was announced on Tuesday, acknowledged organisations operating on the continent that have demonstrated sustained
New business book "Inclusion Driven Performance" by Mariana Fagnilli is released …
Inclusion Driven Performance: A Framework to Unlock Human Potential and Achieve Organizational Excellence by Mariana Fagnilli has been released worldwide. This 334-page business book offers a bold and visionary approach to organizational strategy by placing inclusion not as a moral concept or a compliance requirement, but as a core driver of business performance. Challenging outdated assumptions that frame inclusion as a "nice-to-have," Fagnilli repositions it as a strategic advantage - essential
Mobile Money Market: Revolutionizing Financial Inclusion
The mobile money market has emerged as a transformative force in the global financial landscape, empowering individuals and businesses with convenient and accessible financial services through their mobile phones. This post will delve into the market, exploring its size, share, opportunities, challenges, demand, and trends. Market Size and Share The mobile money market is a substantial segment of the global financial technology industry. While precise figures can vary depending on data sources
18+ Show is here and reaching for National Inclusion
[Accra, 13 November, 2024] - Viewplus, an African-focused entertainment brand under MC Multimedia, proudly announces the launch of its maiden event, 18+ (Spoken Word meets Creativity), in partnership with Beyond the Return Secretariat and the Ghana Tourism Authority. About 18+ Show 18+ Show aims to spread the power of Spoken Word performances (a form of performance poetry) across Ghana and Africa, showcasing talented artists and wordsmiths. The platform offers budding talents a
Ranakpur - Kumbhalgarh Tiger Reserve. Inclusion of Old safari routes
Mana Hotels is pleased to share the progress in the development of the Tiger Reserve in the Ranakpur region of the Kumbhalgarh National Forest reserve of Southern Rajasthan. The site of the reserve located about 6 km from the Ranakpur Jain Temple is located on the highway itself making it easily accessible to the tourists travelling between Udaipur & Jodhpur. The total area under development for this reserve is 211
Enhancing Digital Inclusion: Unveiling Our Comprehensive Accessibility Audit Ser …
We have our accessibility expertEqual access is a basic human right, and discrimination against people with disabilities is strictly prescribed under any circumstances. Inclusion has an even bigger connotation in the digital world. The rapid expansion of technology and the evolving business dynamics have virtually changed the business mindset over the years. Accessibility, often heard in the digital generation, is becoming a necessary mantra for the business world. The simple meaning of